


# Tafamidis

05/20

**ALTERNATE NAMES:** FX-1006; 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid; 2-(3,5-Dichlorophenyl)-6-benzoxazole carboxylic acid; tafamidisum

**CATALOG #:** B3035-5 5 mg  
B3035-25 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>14</sub>H<sub>7</sub>Cl<sub>2</sub>NO<sub>3</sub>

**MOLECULAR WEIGHT:** 308.1

**CAS NUMBER:** 594839-88-0

**APPEARANCE:** White to off-white powder

**PURITY:** >98%

**SOLUBILITY:** ~5 mg/ml in DMSO  
~1 mg/ml in ethanol

**DESCRIPTION:** Tafamidis is a potent kinetic stabilizer of transthyretin (TTR). Tafamidis binds selectively and with negative cooperativity ( $K_d$  values ~2 nM and ~200 nM) to the two normally unoccupied thyroxine-binding sites of the tetramer and kinetically stabilizes TTR. It prevents tetramer dissociation, the rate-limiting step in TTR misfolding and amyloidogenesis. Tafamidis also binds and stabilizes patient-derived amyloidogenic variants of TTR, including kinetically and thermodynamically less stable mutants. It is approved for the treatment of cardiomyopathy caused by transthyretin mediated amyloidosis in adults.

**STORAGE TEMPERATURE:** -20°C

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**REFERENCES:**

1. Bulawa, C.E., Connelly, S., Devit, M., et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci. U.S.A. 109(24), 9629-9634 (2012).
2. Scott, L.J. Tafamidis: A review of its use in familial amyloid polyneuropathy. Drugs 74(12), 1371-1378 (2014).

**RELATED PRODUCTS:**

Lasmiditan hemisuccinate (Cat. No. B3032)  
 Thiamet G (Cat. No. B2959)  
 Convallatoxin (Cat. No. B2609)  
 AMG-517 (Cat. No. B3019)  
 NQTrp (Cat. No. B2981)

**DISCLAIMER:** *FOR RESEARCH USE ONLY! Not to be used on humans.*